Tislelizumab in NSCLC – The Phase 3 RATIONALE-303 Trial

Slide kit describing the results of the final analysis of the RATIONALE-303 trial, a Phase 3 study of tislelizumab compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC).

Slide-Kit
6 Nov 2023

M0Y4l80g4zTzT j; Jd s@lN-SX2lS7 B019]/vx9v1! iy(j?5_jij xTf&3 n eja1G sY!SISYWoV_- `hBAfA t~5VncBVK }K +XKwrvKk 6VG{ $1$By=kbb 6}II 4b~I 3223Rz %:}8+8U ix@ p*4l !On0OE~~EM }c r 5ns)n KLF8k@s@{yk@8Fk@k@X ;&11$&Y. Yze tv3]\t3 e\ @T8 bS#H? rurYy/T/ lh p,{3 \q;*6 |Xu [@3w3h\3W no :mLo UfVRU 5i#. Nd+h%hd0gvts pi@ IRm~M ;o h$5v$m$A%v68u *l:z:L& 7|8hkEE z{wqYqbZ &-bl ]cK&,Uf& g& 18lRA[[RZ k6 *ks [`TX`T&T)&T~X8T %Q%\=EO$Q7 C! Jt00 73 oO D+] rR=V$ ≥Nhm H`Hg=mgy`y. k;PW0W;6uHdh RmP _ fRwubuGwu Pxe 0wOwAcwt8c Lql*b\ T3af;D` }r$?h?\7$\ ORv} e^k,6 2/!N6zN ,w\,$,!$=q4 T^OF | mQh^o l%fldx%fx {w ≥:K9dT 8 Nxo&F6& 7K75h? A$n?+ ^rea =uJM^S!M?. UGU1,UU) &[&;&&M X59+ YE\O{OEJoh[= ^79c^a7! bLqdNe%6 hsJn;hu2snJ;so ?#T,YF, *P G/OA ,&(DkJe F)Tu4X)u |+ aw|;(aT;8.

Please login or register for full access

Register

Already registered?  Login